✦ LIBER ✦

A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies

✍ Scribed by Elena Muraro; Debora Martorelli; Elisa Turchet; Gianmaria Miolo; Simona Scalone; Elisa Comaro; Renato Talamini; Katy Mastorci; Davide Lombardi; Tiziana Perin; Antonino Carbone; Andrea Veronesi; Diana Crivellari; Riccardo Dolcetti

Book ID: 118726825
Publisher: BioMed Central
Year: 2011
Tongue: English
Weight: 724 KB
Volume: 13
Category: Article
ISSN: 1465-5411
DOI: 10.1186/bcr3060

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

370 Primary treatment with weekly doceta

370 Primary treatment with weekly docetaxel (Taxotere) and trastuzumab (Herceptin) for HER-2 overexpressing locally advanced breast cancer

✍ J. Bines; A. Murad; S. Lago; B. Ferrari; J. Andrade; E. Abdo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 175 KB

Neoadjuvant and adjuvant trastuzumab in

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

✍ Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Lluch, Ana; Tjulandin, S 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 294 KB

A phase 2 study of everolimus combined w

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

✍ Hurvitz, Sara A.; Dalenc, Florence; Campone, Mario; OâRegan, Ruth M.; Tjan-Hei 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 327 KB

Sequential administration of dose-dense

Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer

✍ Yago Nieto; José Manuel Aramendía; Jaime Espinós; Susana De la Cruz; Oscar Ferná 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 337 KB

A phase II study of lapatinib for brain

A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients

✍ Iwata, Hiroji; Narabayashi, Masaru; Ito, Yoshinori; Saji, Shigehira; Fujiwara, Y 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 288 KB

Final results of a phase II study ofnab-

Final results of a phase II study ofnab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

✍ Christopher Lobo; Gilberto Lopes; Odalys Baez; Aurelio Castrellon; Annapoorna Fe 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 268 KB